Randomized Block Parallel Controlled Trial for Effectiveness of Perampanel (Fyocampa) Compare to Clonazepam or Levetiracetam Treatment of Epilepsy in Children Less Than 36 Month of Age
Keywords:
perampanel (fyocampa), epilepsy, hyperactivity, Cognitive impairment.Abstract
This study analyzed the effectiveness and safety of perampanel as a treatment for epilepsy in children aged < 36 months. A randomized block parallel controlled trial was conducted on 240 children with epilepsy, with 120 receiving perampanel, 60 receiving clonazepam, and 60 receiving levetiracetam. The results of this study showed the efficacy of perampanel in reducing the symptoms and signs of epilepsy, minimizing the need for hospitalization, and decreasing systemic and neurotoxic side effects and adverse reactions in comparison to clonazepam and levetiracetam. This study concluded that perampanel is an effective and safe drug for young children with epilepsy and should be considered a treatment option. The analysis of symptoms and signs of epilepsy in children under 15 months of age within 12 months of starting treatment showed that the perampanel group had significantly fewer incidences of jerking movements of the arms and legs, loss of consciousness, excessive abnormal crying, and repetitive abnormal movement of the eyes than the clonazepam and levetiracetam groups. Similarly, in children between 16 and 36 months of age, the perampanel group showed significantly fewer incidences of staring and jerking movements of the arms and legs than the clonazepam and levetiracetam groups. These findings suggest that perampanel may be a more effective treatment option for children with epilepsy in this age range. The study found that the use of perampanel (fyocampa) was associated with a significant decrease in systemic and neurotoxic side effects compared with clonazepam and levetiracetam in children under 36 months of age. There was also a more significant reduction in symptoms and signs of epilepsy with perampanel (fyocampa) than with the other two medications. These findings suggest that perampanel (fyocampa) may be a safer and more effective treatment option for young children with epilepsy.
Downloads
References
Buck ML (2016) Use of Perampanel for Refractory Seizures in Pediatric Patients. Pediatric Pharmacotherapy 22 (1). URL: https://med.virginia.edu/pediatrics/wp- content/uploads/sites/237/2015/12/Jan16_Pera mpanel_PedPharmaco.pdf
Casillas‐Espinosa PM, Ali I, & O'Brien TJ (2020) Neurodegenerative pathways as targets for acquired epilepsy therapy development. Epilepsia Open 5 (2): 138-154.
DOI: https://doi.org/10.1002/epi4.12386
Chang F-M, Fan P-C, Weng W-C, Chang C-H, & Lee W-T (2020) The efficacy of perampanel in young children with drug-resistant epilepsy. Seizure 75: 82-86.
DOI: https://doi.org/10.1016/j.seizure.2019.12.024 Dahlin MG, Åmark PE, & Nergårdh AR (2003)
Reduction of seizures with low-dose clonazepam in children with epilepsy. Pediatric neurology 28 (1): 48-52. DOI: https://doi.org/10.1016/S0887-8994(02)00468-X
Ettinger AB, LoPresti A, Yang H, Williams B, Zhou S et al. (2015) Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia 56 (8): 1252-1263. DOI: https://doi.org/10.1111/epi.13054
Finsterer J (2021) Perampanel may be beneficial in Leigh syndrome by its anti-oxidative but not anti-epileptic effect. Brain and Development 43 (2): 360.
DOI: https://doi.org/10.1016/j.braindev.2020.08.008
Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH et al. (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55 (4): 475-482. DOI: https://doi.org/10.1111/epi.12550
IBM SPSS. (2020). Downloading IBM SPSS Statistics 25. Statistics Software Foundation. URL: https://www.ibm.com/support/pages/downloadi ng-ibm-spss-statistics-25
Kearl Y, Abramson TM, Crow E, Lane C, Rose E et al. (2020) Recognition of Active Pediatric Seizures: Prehospital Provider Sensitivity and Specificity. Pediatrics 146 (1): 190–191. DOI: https://doi.org/10.1542/peds.146.1MA3.190
Krauss GL, Perucca E, Ben‐Menachem E, Kwan P, Shih JJ et al. (2014) Long‐term safety of perampanel and seizure outcomes in refractory partial‐onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia 55
(7): 1058-1068. DOI: https://doi.org/10.1111/epi.12643
Li X, Frech F, Plauschinat CA, & Gore M (2021) Real-world hospitalization risk in patients with epilepsy treated with perampanel. Epilepsy & Behavior 114: 107270. DOI: https://doi.org/10.1016/j.yebeh.2020.107270
Lim S, Wu T, Chiang H, Cheng M, Hsieh H et al. (2017) Efficacy and safety of adjunctive perampanel with enzyme-inducing antiepileptic drugs in patients with epilepsy. Journal of the Neurological Sciences 381: 550. DOI: https://doi.org/10.1016/j.jns.2017.08.3757
Minardi C, Minacapelli R, Valastro P, Vasile F, Pitino S et al. (2019) Epilepsy in children: from diagnosis to treatment with focus on emergency. Journal of clinical medicine 8 (1): 39. DOI: https://doi.org/10.3390/jcm8010039
Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC et al. (2012) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. International journal of surgery 10 (1): 28-55. DOI: https://doi.org/10.1016/j.ijsu.2011.10.001
Necdet S (2013) How can we improve the quality of scientific research and publications? Guidelines for authors, editors, and reviewers. Balkan medical journal 2013 (2): 134-135. DOI: https://doi.org/10.5152/balkanmedj.2013.009
Patsalos PN (2015) The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia 56 (1): 12-27. DOI: https://doi.org/10.1111/epi.12865
Renfroe JB, Mintz M, Davis R, Ferreira J, Dispoto S et al. (2019) Adjunctive perampanel oral suspension in pediatric patients from≥ 2 to< 12 years of age with epilepsy: pharmacokinetics, safety,
tolerability, and efficacy. Journal of Child Neurology 34 (5): 284-294. DOI:
https://doi.org/10.1177/0883073819827407 Scheffer IE, Berkovic S, Capovilla G, Connolly
MB, French J et al. (2017) ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58 (4): 512-521. DOI: https://doi.org/10.1111/epi.13709
Süt N (2014) Study Designs in Medicine. Balkan medical journal 31 (4): 273-227. DOI: https://doi.org/10.5152/balkanmedj.2014.1408
Tremblay G, Howard D, Tsong W, Patel V, & De Rosendo J (2018) Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in
epilepsy: A Spanish perspective. Epilepsy & Behavior 86: 108-115. DOI: https://doi.org/10.1016/j.yebeh.2018.06.002
Villanueva V, Montoya J, Castillo A, Mauri‐Llerda JÁ, Giner P et al. (2018) Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12‐month GENERAL study. Epilepsia
(9): 1740-1752. DOI: https://doi.org/10.1111/epi.14522
Zhang L, Wang C, & Li W (2018) A meta-analysis of randomized controlled trials on levetiracetam in the treatment of pediatric patients with epilepsy. Neuropsychiatric disease and treatment 14: 769-779. DOI: https://doi.org/10.2147/ndt.s151413
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
